Bridgebio Pharma vs Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International is the larger business, with $678m of revenue in fiscal 2025 against $502m for Bridgebio Pharma (1.3 times as much). Bridgebio Pharma grew faster (126.3% against 60.1%). Kiniksa Pharmaceuticals International kept more of each dollar of sales as profit: a net margin of 8.7% against -144.4%.
| Latest fiscal year | Bridgebio PharmaBBIO, 2025 | Kiniksa Pharmaceuticals InternationalKNSA, 2025 |
|---|---|---|
| Revenue | $502m | $678m |
| Revenue growth | 126.3% | 60.1% |
| Net income | −$725m | $59.0m |
| Operating margin | -104.2% | 11.4% |
| Net margin | -144.4% | 8.7% |
| Return on equity | — | 11.7% |
| Free cash flow | −$447m | $136m |
| Cash | $570m | $166m |
| Total debt | $2.01bn | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $48.3m | — |
| Employees | 834 | 366 |
| Market value | $14.64bn | $7.91bn |
| Price vs our value range | — | Above our value range |
| Moat score | 8 (Weak) | 16 (Weak) |
| Insider trades, 12 months | 0 buys, 143 sales | 0 buys, 37 sales |